// App-Quantinova.ai

FRI0223 : LONG-TERM TARGETED SAFETY EVENT RATES IN RA PATIENTS FOLLOWING INITIATION OF RITUXIMAB: INTERIM ANALYSIS FROM SUNSTONE REGISTRY

Researchers

Presenter

  • D. Furst

Principal Investigators

  • K. L. Winthrop

  • K. A. Alexander

  • A. Vashishtha

  • S. F. Francom

  • K. G. Saag

Medical Centers

  • Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

Locations

  • United States

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Genetic Disorder

  • Musculoskeletal

Disease

  • Multifocal leukoencephalopathy

  • Ischemic stroke

  • Myocardial infarction

  • Deep vein thrombosis

  • Rheumatoid arthritis

  • Pulmonary embolism

  • Tuberculosis

  • Venous thrombosis

  • Inflammatory Arthritis

  • Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved